What Does Wall Street Think About Amicus Therapeutics (FOLD)?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks with high potential. On September 18, Needham analyst Gil Blum upgraded the rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) to a Buy, setting a price target of $14.00.

Similarly, Morgan Stanley analyst Maxwell Skor also maintained a Buy rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) on September 17, setting a $12.00 price target.

The analyst consensus rating on Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a Strong Buy, and the stock’s median price target of $8.41 implies an upside of 78.25% from current levels.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases.

Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

While we acknowledge the potential of FOLD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.